Xencor | XNCR - Current Assets


Xencor reported $518.44M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Xencor USD 518.44M 5.29M Sep/2025